Medivation Dimebon Active Clinical Trials

Victor
By -
0
The Google keyword search "Dimebon" brings visitors to the Alzheimer's Reading Room every day. It is easy for me to understand why. Dimebon is the search for the "holy grail" when it comes to a cure or treatment for Alzheimer's disease.

For more information on Dimebon read these articles:

Medivation Dimebon Connection Study Complete, Additional Phase 3 Trials Still Open

Is Pfizer Medivation's Dimebon a $1.5 Billion Blockbuster Drug?

If you want to see all the clinical trials for Dimebon--recruiting, not yet recruiting, active but not recruiting, and completed--go here.

If you are thinking about applying for a clinical trial--go for it. There is no downside and the process is easy and non-threatening. Call the number on the clinical trial page, and if you are qualified go in for the initial interview.


Subscribe to the Alzheimer's Reading Room
Enter Your Email Address

Pfizer and Medivation Present Positive Safety and Tolerability Data on Dimebon in Combination With Donepezil (Aricept)

Pfizer (NYSE: PFE) and Medivation, Inc. (Nasdaq: MDVN) today announced that new Phase 1 data showed that the investigational drug dimebon (latrepirdine)* was well tolerated when used in combination with donepezil HCI tablets, the leading Alzheimer's disease (AD) medication worldwide, in patients with mild-to-moderate Alzheimer's disease.
Bob DeMarco is the editor of the Alzheimer's Reading Room and an Alzheimer's caregiver. Bob has written more than 1,200 articles with more than 9,000 links on the Internet. Bob resides in Delray Beach, FL.
Popular articles on the Alzheimer's Reading Room


Original content Bob DeMarco, the Alzheimer's Reading Room


Post a Comment

0Comments

Post a Comment (0)